The incidence of immunologic reactions in patients with Gaucher's disease (GD) on enzymatic replacement therapy with imiglucerase is about 17% and related with the presence of non-neutralizing immunoglobulin G antibodies.
The clinical trials with a new enzyme obtained in human cells (GA-GCB-velaglucerase) have demonstrated absence of immune reactions and no antibodies against the enzyme in spite of some patients had previous developed antibodies against imiglucerase.
We present 2 clinical cases of patients diagnosed with EG in childhood and who developed antibodies and important imiglucerase immunoallergic adverse reaction during the imiglucerase perfusion, indicating systematic administration of steroids and antihistamines prior to each perfusion and perfusion time > 4h.
2012-01-10
Spa.
Medicina clinica
Atención Primaria Delicias Norte, Fundación Española para el Estudio y Tratamiento de la Enfermedad de Gaucher, Zaragoza, Spain. platre05 [at] gmail.com
Med Clin (Barc). 2011 Sep;137 Suppl 1():39-42
© Galenicom 1999-2013